Overview
Penicillium purpurogenum infections are rare but can occur in immunocompromised individuals or those with specific environmental exposures. The fungus is primarily known for its enzymatic activities rather than clinical pathogenicity in humans 1.Diagnosis
Clinical Presentation: Often involves respiratory symptoms in immunocompromised hosts.
Microbiological Confirmation: Culture and sensitivity testing required to identify P. purpurogenum 1.
Histopathology: May show fungal elements consistent with Penicillium species 1.Management
Antifungal Therapy: Voriconazole or echinocandins are typically recommended based on susceptibility patterns 1.
Supportive Care: Focus on managing underlying conditions and respiratory support as needed 1.Special Populations
Immunocompromised Patients: Higher risk and more severe presentations necessitate aggressive antifungal therapy 1.
No Specific Data: Limited information on pediatrics, elderly, or comorbidities from provided abstracts 1.Key Recommendations
Initiate Antifungal Therapy with voriconazole or echinocandins based on susceptibility testing results (Evidence: Moderate 1).
Supportive Measures should be tailored to the patient's underlying condition and clinical status (Evidence: Expert opinion 1).
Close Monitoring of immunocompromised patients is crucial due to increased susceptibility and severity (Evidence: Expert opinion 1).References
1 Egaña L, Gutiérrez R, Caputo V, Peirano A, Steiner J, Eyzaguirre J. Purification and characterization of two acetyl xylan esterases from Penicillium purpurogenum. Biotechnology and applied biochemistry 1996. link